Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Blood cancers, Myelofibrosis
Closed
Phase 1
This trial is looking at the drugs ruxolitinib and panobinostat as treatment for myelofibrosis.
Myelofibrosis (pronounced my-eh-lo-fy-bro-sis) is a rare blood disorder. It is a condition that causes scarring of the . A small number of people with myelofibrosis go on to develop acute myeloid leukaemia.
Myelofibrosis can develop without having had any other condition. This is called primary myelofibrosis (PMF). It can also develop in people who have polycythaemia vera or essential thrombocythaemia. This is called secondary myelofibrosis. This trial is for people with either primary or secondary myelofibrosis.
The trial is looking at a combination of 2 drugs called ruxolitinib (also known as INC424) and panobinostat (also known as LBH589). They are both types of biological therapy.
Ruxolitinib is a cancer growth blocker. It stops signals that cancer cells use to divide and grow. Doctors can already use ruxolitinib to treat myelofibrosis.
Panobinostat is a drug that blocks that cells need to grow and divide. Researchers are testing it in clinical trials for different types of cancer.
This is the first time that the combination of these 2 drugs has been tested in people. The aims of the trial are to
Find the highest safe doses of the drugs that you can have at the same time
See what happens to the drugs in your body
Learn more about the side effects
Recruitment start: 1 September 2011
Recruitment end: 31 January 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Claire Harrison
Novartis
Last reviewed: 15 February 2016
CRUK internal database number: 10689